Xynomic Pharma focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies.Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and rest of the world. Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is the 52-week high for Bison Capital Acquisition Corp?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Bison Capital Acquisition Corp 52 week high is $14.26 as of September 02, 2026.
What is the 52-week low for Bison Capital Acquisition Corp?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Bison Capital Acquisition Corp 52 week low is $8.82 as of September 02, 2026.
What is Bison Capital Acquisition Corp stock price today?
Bison Capital Acquisition Corp stock price today is $10.00.
What was Bison Capital Acquisition Corp stock price yesterday?
Bison Capital Acquisition Corp stock price yesterday was $10.00.
What is the 50-day moving average of Bison Capital Acquisition Corp?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Bison Capital Acquisition Corp 50-day moving average is $8.82.